Literature DB >> 25317812

The impact of small doses of LPS on NASH in high sucrose and high fat diet induced rats.

J-H Guo1, D-W Han, X-Q Li, Y Zhang, Y-C Zhao.   

Abstract

OBJECTIVE: We investigated the impact of small doses of lipolysaccharide (LPS) on the development of NASH in the context of a high sucrose and high fat diet in rats.
MATERIALS AND METHODS: Male Wistar rats were randomly divided into groups fed a synthetic diet (n=8), a regular diet (n=8), a synthetic diet + LPS (n=8) or saline (n=8) and a regular diet + LPS (n=8) or saline (n=8). The LPS (or saline) was administered from the 6th week on (0.5 mg/kg) by subcutaneous injection every two days under the same conditions with free access to water and food. At the end of the 9th week the animals were euthanized and the liver tissue dissected for analysis. Hematoxylin and eosin (HE) and Von Gieson's (VG) staining was performed on parafin embedded sections to observe the pathological changes of the liver, the degree of fibrosis, and infiltrative lymphocytes were counted in the liver tissue.
RESULTS: We quantitatively measured the levels of LPS in the plasma of rats, ALT activity, and TNF-alpha. We found that the synthetic diet + LPS group showed severe steatosis, and was associated with bridging necrosis and mild fibrosis when compared to the group fed a Synthetic diet + saline. In addition, the amount of infiltrative lymphocytes and the level of plasma ALT and TNF-alpha in the synthetic diet + LPS group were significantly increased. The difference observed were statistically significant (p < 0.05).
CONCLUSIONS: Small doses of LPS promote the development of NASH induced by a high sucrose and high fat.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25317812

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  6 in total

1.  Saroglitazar Deactivates the Hepatic LPS/TLR4 Signaling Pathway and Ameliorates Adipocyte Dysfunction in Rats with High-Fat Emulsion/LPS Model-Induced Non-alcoholic Steatohepatitis.

Authors:  Noha F Hassan; Somaia A Nada; Azza Hassan; Mona R El-Ansary; Muhammad Y Al-Shorbagy; Rania M Abdelsalam
Journal:  Inflammation       Date:  2019-06       Impact factor: 4.092

Review 2.  Precision medicine in alcoholic and nonalcoholic fatty liver disease via modulating the gut microbiota.

Authors:  Sena Bluemel; Brandon Williams; Rob Knight; Bernd Schnabl
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-09-29       Impact factor: 4.052

3.  Extracts of Salvia-Nelumbinis Naturalis Ameliorate Nonalcoholic Steatohepatitis via Inhibiting Gut-Derived Endotoxin Mediated TLR4/NF-κB Activation.

Authors:  Xiangbing Shu; Miao Wang; Hanchen Xu; Yang Liu; Jie Huang; Zemin Yao; Li Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2017-07-31       Impact factor: 2.629

4.  Modulation of hepatic stellate cells by Mutaflor® probiotic in non-alcoholic fatty liver disease management.

Authors:  Noha M Hany; Sanaa Eissa; Manal Basyouni; Amany H Hasanin; Yasmin M Aboul-Ela; Nagwa M Abo Elmagd; Iman F Montasser; Mahmoud A Ali; Paul J Skipp; Marwa Matboli
Journal:  J Transl Med       Date:  2022-07-30       Impact factor: 8.440

5.  mRNA-miRNA-lncRNA Regulatory Network in Nonalcoholic Fatty Liver Disease.

Authors:  Marwa Matboli; Shaimaa H Gadallah; Wafaa M Rashed; Amany Helmy Hasanin; Nada Essawy; Hala M Ghanem; Sanaa Eissa
Journal:  Int J Mol Sci       Date:  2021-06-24       Impact factor: 5.923

6.  Hepatic Inflammatory Response to Exogenous LPS Challenge is Exacerbated in Broilers with Fatty Liver Disease.

Authors:  Wenqing Mei; Yarong Hao; Huilin Xie; Yingdong Ni; Ruqian Zhao
Journal:  Animals (Basel)       Date:  2020-03-19       Impact factor: 2.752

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.